Serum Institute of India has a history of winning shares in established vaccine markets by undercutting the competition. And now it has bought the rights to a tuberculosis vaccine it believes can beat shots by Merck and Sanofi on effectiveness, as well as cost.
Rockville, MD-based Sequella has snagged global rights to a mid-stage antibiotic from Pfizer, which has been jettisoning programs that don't fit squarely into its core disciplines following a top-to-bottom restructuring of its big pipeline. And the biotech says it's on its way to rounding up a $38 million C round to fund a pivotal study for its new therapy.
While a closely watched study of Gates-backed TB vaccine MVA85A failed to produce the desired results to guard against infection in infants, a dozen more vaccine candidates are being tested in humans. Regardless of results, the first efficacy trial of a new TB vaccine is a milestone.
A closely watched study of a new Gates-backed tuberculosis vaccine--MVA85A--failed to deliver desperately hoped-for data that it could guard infants against the lethal disease. Investigators said the jab failed to prove that it had a comparable effect as that seen in a study involving adults.
The global fight against tuberculosis is about to yield some big news. Next week researchers are reporting results a mid-stage study of the leading next-generation vaccines against TB, with supporters from the Bill & Melinda Gates Foundation and elsewhere hoping for a breakthrough for populations at risk of infection.
On the last day of the year the FDA came through with a rapid-fire approval of Johnson & Johnson's bedaquiline, the first new treatment for drug-resistant tuberculosis in four decades.
University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.
The Bill & Melinda Gates Foundation awarded $10 million to Seattle, WA-based IDRI for formulating new and improved vaccine adjuvants, focusing predominantly on tuberculosis.
Johnson & Johnson's Janssen has taken a step closer to gaining approval for the first new way of combating tuberculosis in decades. And an FDA advisory committee voted 18-0 in favor of efficacy of the experimental med, bedaquiline, for combating multidrug-resistant cases of the infection.
A Danish-made tuberculosis vaccine sickened more than 100 children in Romania, according to a European Centre for Disease Prevention and Control report.